# US 2010/0074955 A1 · Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074955 A1
- Document ID: US20100074955A1
- Status: Published application
- Kind: A1
- Application number: 12/441,874
- Filed: 2007-09-18
- Published: 2010-03-25
- Earliest claimed: 2006-09-19
- Assignees: Laboratorios Del Dr. Esteve, S.A.
- Inventors: Helmut Heinrich Buschmann; Xavier Codony-Soler
- Web page: https://patentgrep.com/patent/US20100074955A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/10: Laxatives
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

## Claims

### Claim 1

An active substance combination comprising:
a first component comprising one or more compounds with 5-HT6 receptor affinity; and
a second component comprising one or more NMDA-receptor ligands.

### Claim 2 (depends on 1)

The combination according to claim 1, wherein the binding of at least one said compound of the first component to a 5-HT6-receptor is determined by a Ki value of less than 7000 nM.

### Claim 3 (depends on 1)

The combination according to claim 1, wherein at least one said NMDA-receptor ligand of the second component acts as an NMDA-receptor antagonist.

### Claim 4 (depends on 1)

The combination according to claim 1, wherein the binding of at least one said NMDA-receptor ligand of the second component to an NMDA-receptor is determined by an EC50 or IC50 value of less than 300 μM.

### Claim 5 (depends on 1)

The combination according to claim 1, wherein at least one said compound of the first component is selected from the group consisting of:
(i) benzoxazinone-derived sulfonamide compounds of general formula (Ia)
wherein
R1a, R2a, R3a and R4a, independently of one another, each represent a hydrogen atom; halogen; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl- or heteroaryl radical; nitro; cyano; —O—R10a; —O—(C═O)—R11a; —(C═O)—OR11a; —SR12a; —SOR12a; —SO2R12a; —NH—SO2R12a; —SO2NH2 or —NR13aR14a;
R5a represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a saturated or unsaturated, unsubstituted or at least mono-substituted, cycloaliphatic radical;
R6a, R7a, R8a, R9a, independently of one another, each represent a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, cycloaliphatic radical; a cyano group or a —C(═O)—OR15a moiety;
Wa represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; a —NR16aR17a moiety, or a —C(═O)—R18a moiety;
R10a represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R11a represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R12a represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R13a and R14a, independently of one another, each represent a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical; or
R13a and R14a together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which is unsubstituted or at least mono-substituted;
R15a represents a hydrogen atom; an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R16a represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R17a represents an unbranched or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; and
R18a represents an unsubstituted or at least mono-substituted aryl radical;
or one of its stereoisomers, its racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a solvate;
(ii) indole-derived sulfonamide compounds of general formula (Ib)
wherein
R1b represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; a —(CH2)mb—NR13bR14b moiety with mb=0, 1, 2, 3, 4 or 5; a —C(═O)—R8b moiety; a —S(═O)2—R9b moiety; or a —S(═O)2—C(H)AbBb moiety;
R2b represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —NH2; —SH; —OH; —CN; —C(═O)—OH; —O—R10b; —S—R11b; —C(═O)—OR12b; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R3b represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10b; —S—R11b; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; a —CH(OC2H5)—CH2—NR13bR14b moiety or a —(CH2)nb—NR13bR14b moiety with nb=0, 1, 2, 3, 4 or 5; a —S(═O)2—R9b moiety; a —S(═O)2—C(H)AbBb moiety; or a —C(═O)—(CH2)pb—C(═O)—N-DbEb moiety with pb=0, 1, 2, 3, 4 or 5;
R4b, R5b, R6b and R7b, independently of one another, each represent a hydrogen atom; —NO2; —NH2; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—R8b; —S(═O)2—R9b; —O—R10b; —R11b; —C(═O)—OR12b; —N(R15b)—S(═O)2—R16b; —NH—R17b; —NR18bR19b; —C(═O)—NHR20b, C(═O)—NR21bR22b; —S(═O)2—NHR23b; —S(═O)2—NR24bR25b; —O—C(═O)—R26b; —NH—C(═O)—R27b; —NR28b—C(═O)—R29b; NH—C(═O)—O—R30b; NR31b—C(═O)—O—R32b; —S(═O)2—O—R33b; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, wherein at least one of the substituents R4b, R5b, R6b and R7b represents a —N(R15b)—S(═O)2—R16b moiety;
R8b, R12b, R17b, R18b, R19b, R20b, R21b, R22b, R23b, R24b, R25b, R26b, R27b, R28b, R29b, R30b, R31b, R32b and R33b, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R9b represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R10b and R11b, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R13b and R14b, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13b and R14b together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R15b represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O)2—R16b moiety;
R16b represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
Ab and Bb together with the bridging carbon form an unsubstituted or at least mono-substituted, saturated or unsaturated cycloaliphatic ring; and
Db and Eb together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring; or
Db and Eb, independently of one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(iii) indazolyl- and (2,3)-dihydro-indolyl-derived sulfonamide compounds of general formula (Ic)
wherein
Xc—Yc from left to right represents:
(a) CR1c═N and Zc is N[(CH2c)ncR6c];
(b) CR7c═N, Zc is NH, R7c represents the following moiety
Ac represents CH or N, and Bc represents NR8c, O or S;
(c) C[(CH2c)ncR9c]═N and Zc is NR10c; or
(d) CH2—CH2 and Zc is N[(CH2c)ncR11e],
wherein nc is 0, 1, 2, 3 or 4;
R1c represents a hydrogen atom; NO2; —NH2; —SH; —OH; —CN; —C(═O)—R12c; —OR13c; —SR14c; —F; —Cl, —Br; —I; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R2c, R3c, R4c and R5c, independently of one another, each represent a hydrogen atom; —NO2; —NH2; —SH; —OH; —CN; —C(═O)—H; —C(═O)—R12c; —OR13c; —SR14c; —N(R15c)—S(═O)2—R16c; —NH—R17c; —NR18cR19c; —F; —Cl, —Br; —I; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, wherein at least one of the substituents R2c, R3c, R4c and R5c represents a —N(R15c)—S(═O)2—R16c moiety;
R6c, R9c and R11c, independently of one another, each represent a —NR20cR21c radical or a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical;
R8c represents —C(═O)—R22c; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R10c represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical-; or a —S(═O)2—R23c moiety;
R12c, R13c, R14c, R17c, R18c and R19c, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R15c represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a —S(═O)2—R24c moiety;
R16c and R24c, independently of one another, each represent an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R20c and R21c, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R20c and R21c together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R22c represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical; and
R23c represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical, which may be bonded via a linear or branched, unsubstituted or at least mono-substituted alkylene, alkenylene or alkinylene group and/or which may be condensed with an unsubstituted or at least mono-substituted mono- or bicyclic ring system; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(iv) phenyl-piperazine-derived compounds of general formula (Id)
wherein
Xd represents a —NR1dR2d moiety;
R1d represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted radical selected from the group consisting of adamantyl, bicyclo[2.2.1]heptyl and bicyclo[3.1.1]heptyl; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; or a —C(═O)—R12d moiety; and
R2d represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R1d and R2d together with the bridging nitrogen form a saturated, unsaturated or aromatic heterocyclic ring;
R3d represents or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R4d, R5d and R6d, independently of one another, each represent a hydrogen atom or a halogen atom; or
R4d and R5d together with the bridging carbon atoms form an unsubstituted 5- or 6-membered heterocyclic ring which contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which together with the phenyl ring which it is fused with forms a 9- or 10-membered bicyclic aromatic ring system;
R7d and R8d, independently of one another, each represent a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R9d and R10d, independently of one another, each represent a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R11d represents a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; a —C(═O)—R13d moiety; or a —S(═O)2—R14d moiety;
R12d represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical; and
R13d and R14d, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(v) phenyl-piperazine-derived compounds of general formula (Ie)
wherein
Xe represents —CN, —C(═O)—OH, —C(═O)—OR4e, —O—R5e, —NH2, —NR6e—C(═O)—R7e, —NH—S(═O)2—R8e or —NH—R9e;
R1e represents a hydrogen atom; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical; and
R2e represents a hydrogen atom or a —C(═O)—R10e moiety; or
R1e and R2e together with the bridging nitrogen form a nitro (NO2)-group or an unsubstituted or at least mono-substituted 5- or 6-membered heteroaryl radical;
R3e represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R4e represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R5e represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R6e represents a hydrogen atom or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R7e represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R8c represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R9e represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical; and
R10e represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
or one of its stereoisomers, a racemate or in form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof; and
(vi) tetrahydroisoquinoline-derived sulfonamide compounds of general formula (If):
wherein
R1f represents a hydrogen atom; a —C(═O)—OR37f moiety; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical;
R2f, R3f, R4f and R5f, independently of one another, each represent a hydrogen atom; F, Cl, Br, I, —NO2; —NH2; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—R6f; —S(═O)—R7f; —S(═O)2—R7f; —OR8f; —SR9f; —C(═O)—OR10f; —N(R11f)—S(═O)2—R12f; —NR13fR14f; —NH—R15f; —C(═O)—NR16fR17f; C(═O)—NHR18f; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, wherein at least one of the substituents R2f, R3f, R4f and R5f represents a —N(R11f)—S(═O)2—R12f moiety;
R6f, R7f, R8f, R9f, R10f, R13f, R14f, R15f, R16f, R17f and R18f, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R11f represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; and
R12f represents a phenyl radical of general formula (Af),
wherein
R19f, R20f, R21f, R22f and R38f, independently of one another, each represent a hydrogen atom; F, Cl, Br, I, —NO2; —NH2; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—R23f; —S(═O)—R24f; —S(═O)2—R24f; —OR25f; —SR26f; —C(═O)—OR27f; —N(R28f)—S(═O)2—R29f; —NH—S(═O)2—R30f; —NR31fR32f; —NH—R33f; —C(═O)—NHR34f; —C(═O)—NR35fR36f; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical;
R23f, R27f, R28f, R29f and R30f, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R24f, R26f, R31f, R32f and R33f each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R25f, R34f, R35f and R36f each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; and
R37f represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a salt thereof, or a corresponding solvate thereof.

### Claim 6 (depends on 5)

The combination according to claim 5, wherein the indole-derived sulfonamide is selected from the group consisting of:
(i) compounds of general formula (Ih)
wherein
R1h represents a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or a —(CH2)mh—NR13hR14h moiety with mh=0, 1, 2, 3, 4 or 5;
R2h represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10h; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R3h represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10h; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; or a —(CH2)nh—NR13hR14h moiety with nh=0, 1, 2, 3, 4 or 5;
R4h, R5h and R7h, independently of one another, each represent a hydrogen atom; —NO2; —CN; —O—R10h; —C(═O)—OR12h; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R10h represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R13h and R14h, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13h and R14h together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R15h represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O)2—R16h moiety; and
R16h represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(ii) compounds of general formula (Ik)
wherein
R1k represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted phenyl radical or an unsubstituted or at least mono-substituted benzyl radical;
R3k represents a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or a —(CH2)nk—NR13kR14k moiety with nk=0, 1, 2, 3, 4 or 5;
R13k and R14k, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13k and R14k together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R15k represents a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; and
R16k represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(iii) compounds of general formula (Im)
wherein
R1m represents a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or a —(CH2)mm—NR13mR14m moiety with mm=0, 1, 2, 3, 4 or 5;
R2m represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10m; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R3m represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10m; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R4m, R6m and R7m, independently of one another, each represent a hydrogen atom; —NO2; —CN; —O—R10m; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R10m represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical, which may be bonded via a linear or branched alkylene group;
R13m and R14m, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13m and R14m together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R15m represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O)2—R16m moiety; and
R16m represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(iv) compounds of general formula (In)
wherein
R1n represents a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or a —(CH2)mn—NR13nR14n moiety with mn=0, 1, 2, 3, 4 or 5;
R2n represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10n; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R3n represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10n; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; or a —(CH2)nm—NR13nR14n moiety with nm=0, 1, 2, 3, 4 or 5;
R5n, R6n and R7n, independently of one another, each represent a hydrogen atom; —NO2; —CN; —O—R10n; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R10n represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R13n and R14n, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13n and R14n together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R15n represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O)2—R16n moiety; and
R16n represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(v) compounds of general formula (Io)
wherein
R1o represents a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or a —(CH2)mo—NR13oR14o moiety with mo=0, 1, 2, 3, 4 or 5;
R2o represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10o; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R3o represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —CN; —O—R10o; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; an unsubstituted or at least mono-substituted aryl or heteroaryl radical; a —CH(OC2H5)—CH2—NR13oR14o moiety or a —(CH2)no—NR13oR14o moiety with no=0, 1, 2, 3, 4 or 5;
R4o, R5o and R6o, independently of one another, each represent a hydrogen atom; —NO2; —CN; —O—R10o; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical
R10o represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R13o and R14o, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13o and R14o together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring;
R15o represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O)2—R16o moiety; and
R16o represents an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;
(vi) compounds of general formula (Ip)
wherein
R1p represents a —S(═O)2—R9p moiety or a —S(═O)2—C(H)ApBp moiety;
R2p represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —OH; —CN; —O—R10p; —S—R11p; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical;
R3p represents a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical; or a —(CH2)np—NR13pR14p moiety with np=0, 1, 2, 3, 4 or 5;
R4p, R5p, R6p and R7p, independently of one another, each represent a hydrogen atom; —NO2; —NH2; —OH; —CN; —C(═O)—R8p; —O—R10p; —S—R11p; —NH—R17p; —NR18pR19p; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical;
R8p represents a hydrogen atom or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R8p, R17p, R18p and R19p, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R9p represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical;
R10p and R11p, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R13p and R14p, independently of one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or
R13p and R14p together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring; and
Ap and Bp together with the bridging carbon form an unsubstituted or at least mono-substituted, saturated or unsaturated cycloaliphatic ring;
or one of its stereoisomers, a racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof; and
(vii) compounds of general formula (Iq)
wherein
R1q represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; a —C(═O)—R8q moiety; a —S(═O)2—R9q moiety;
R2q represents a hydrogen atom; —F; —Cl; —Br; —I; —NO2; —NH2; —SH; —OH; —CN; a linear or branched, saturated or unsaturated, unsubstituted or at least Mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted containing cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R4q, R5q, R6q and R7q, independently of one another, each represent a hydrogen atom; —NO2; —NH2; —SH; —OH; —CN; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—R8q; —S(═O)2—R9q; —O—R10q; —S—R11q; —C(═O)—OR12q; —N(R15q)—S(═O)2—R16q; —NH—R17q; —NR18qR19q; —C(═O)—NHR20q, —C(═O)—NR21qR22q; —S(═O)2—NHR23q; —S(═O)2—NR24qR25q; —O—C(═O)—R26q; —NH—C(═O)—R27q; —NR28q—C(═O)—R29q; NH—C(═O)—O—R30q; NR31q—C(═O)—O—R32q; —S(═O)2—O—R33q; a halogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; wherein at least one of the substituents R4q, R5q, R6q and R7q represents a —N(R15q)—S(═O)2—R16q moiety;
R8q, R12q, R17q, R18q, R19q, R20q, R21q, R22q, R23q, R24q, R25q, R26q, R27q, R28q, R29q, R30q, R31q, R32q and R33q, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical;
R9q represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R10q and R11q, independently of one another, each represent a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
R15q represents a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical or a —S(═O)2—R16g moiety;
R16q represents a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical; and
Dq and Eq together with the bridging nitrogen form an unsubstituted or at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring; or
Dq and Eq, independently of one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated, unsubstituted or at least mono-substituted aliphatic radical; a saturated or unsaturated, unsubstituted or at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical; or an unsubstituted or at least mono-substituted aryl or heteroaryl radical;
or one of its stereoisomers, racemate or in the form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

### Claim 7 (depends on 1)

The combination according to claim 1, wherein at least one said NMDA-receptor ligand of the second component is selected from the group consisting of 3-((−)-2-carboxypiperazin-4-ylpropyl-1-phosphate (CPP); 3-(2-carboxypiperazin-4-yl)-propenyl-1-phosphonate (CPP-ene); 1-(cis-2-carboxypiperidine-4-yl)methyl-1-phosphonic acid (CGS 19755); D-2-Amino-5-phosphonopentanoic acid (AP5); 2-amino-phosphonoheptanoate (AP7); D,L-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid carboxyethyl ester (CGP39551); 2-amino-4-methyl-5-phosphono-pent-3-enoic acid (CGP 40116); (4-phosphono-but-2-enylamino)-acetic acid (PD 132477); 2-amino-4-oxo-5-phosphono-pentanoic acid (MDL 100,453); 3-((phosphonylmethyl)-sulfinyl)-D,L-alanine; amino-(4-phosphonomethyl-phenyl)-acetic acid (PD 129635); 2-amino-3-(5-chloro-1-phosphonomethyl-1H-benzoimidazol-2-yl)-propionic acid; 2-amino-3-(3-phosphonomethyl-quinoxalin-2-yl)-propionic acid; 2-amino-3-(5-phosphonomethyl-biphenyl-3-yl)-propionic acid (SDZ EAB 515); 2-amino-3-[2-(2-phosphono-ethyl)-cyclohexyl]-propionic acid (NPC 17742); 4-(3-phosphono-propyl)-piperazine-2-carboxylic acid (D-CPP); 4-(3-phosphono-allyl)-piperazine-2-carboxylic acid (D-CPP-ene); 4-phosphonomethyl-piperidine-2-carboxylic acid (CGS 19755); 3-(2-phosphono-acetyl)-piperidine-2-carboxylic acid (MDL 100,925); 5-phosphono-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (SC 48981); 5-(2-phosphono-ethyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (PD 145950); 6-phosphonomethyl-decahydro-isoquinoline-3-carboxylic acid (LY 274614); 4-(1H-tetrazol-5-ylmethyl)-piperidine-2-carboxylic acid (LY 233053 and 235723); 6-(1H-Tetrazol-5-ylmethyl)-decahydro-isoquinoline-3-carboxylic acid (LY 233536); ketamine; phencyclidine; dextromethorphan; dextrorphan; dexoxadrol; dizocilpine (MK-801); remacemide; thienylcyclohexylpiperidine (TCP); N-allylnometazocine (SKF 10,047); cyclazocine; etoxadrol; (1,2,3,4,9,9a-hexahydro-fluoren-4a-yl)-m-ethyl-amine (PD 137889); (1,3,4,9,10,10a-hexahydro-2H-phenanthren-4a-yl)-methyl-amine (PD 138289); PD 138558; tiletamine; kynurenic acid; 7-chloro-kynurenic acid; memantine; quinoxalinediones; amantadine; eliprodil; iamotrigine; riluzole; aptiganel; flupirtine; celfotel; levemopamil; 1-(4-hydroxy-phenyl)-2-(4-phenylsulfanyl-piperidin-1-yl)-propan-1-one; 2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-1-naphthalen-2-yl-ethanone (E 2001); 3-(1,1-dimethyl-heptyl)-9-hydroxymethyl-6,6-dimethyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol (HU-211); 1-{4-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2-methoxy-phenyl}-1H-[1,2,4]triazole-3-carboxylic acid amide (CGP 31358); acetic acid 10-hydroxy-7,9,7′,9′-tetramethoxy-3,3′-dimethyl-3,4,3′,4′-tetrahydro-1H,1′H-[5,5]bi[benzo[g]isochromenyl]-4-yl ester (ES 242-1); 14-hydroxy-11-isopropyl-10-methyl-5-octyl-10,13-diaza-tricyclo[6.6.1.04,1-5]pentadeca-1,4,6,8(15)-tetraen-12-one; and 4,5-dioxo-4,5-dihydro-1H-benzo-[g]indole-2,7,9-tricarboxylic acid (PQQ).

### Claim 8 (depends on 1)

The combination according to claim 1, comprising 1-99% by weight of the first component and 99-1% by weight of the second component, referring to the total weight of both components.

### Claim at position 9

9-13. (canceled)

### Claim 14

A pharmaceutical formulation, comprising an active substance combination, the active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands and one or more pharmacologically acceptable adjuvants.

### Claim 15 (depends on 14)

The pharmaceutical formulation according to claim 14, formulated as solid, liquid, or semi-liquid pharmaceutical forms.

### Claim 16 (depends on 14)

The pharmaceutical formulation according to claim 14, formulated as multiple particles, compacted in a tablet, filled in a capsule or suspended in a suitable liquid.

### Claim 17 (depends on 14)

The pharmaceutical formulation according to claim 14, formulated for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonal, rectal, transdermal, nasal or intracerebroventricular application.

### Claim 18 (depends on 14)

The pharmaceutical formulation according to claim 14, wherein at least one of the first or second components of the active substance combination is present at least partially in sustained-release form.

### Claim 19 (depends on 18)

The pharmaceutical formulation according to claim 18, wherein the formulation is a medicament having at least one coating or at least one matrix comprising at least one sustained-release material, which sustains active substance release.

### Claim 20 (depends on 19)

The pharmaceutical formulation according to claim 19, wherein the sustained-release material is based on water-insoluble, natural, semisynthetic or synthetic polymer, or a natural wax or fat or fatty alcohol or semisynthetic or synthetic fatty acid, or any combination thereof.

### Claim 21 (depends on 20)

The pharmaceutical formulation according to claim 20, wherein the water-insoluble polymer is based on an acrylic resin.

### Claim 22 (depends on 20)

The pharmaceutical formulation according to claim 20, wherein the water-insoluble polymer is a cellulose derivative.

### Claim at position 19

23-25. (canceled)

### Claim 26

A method for simultaneous NMDA-receptor inhibition and 5-HT6-receptor regulation, said method comprising administering to a patient in need of such a treatment a therapeutically effective amount of an active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands.

### Claim 27

A method of treatment and/or prophylaxis of disorders related to food ingestion for prophylaxis and/or treatment of gastrointestinal tract disorders, for prophylaxis and/or treatment of Metabolic Syndrome, Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatory diseases, immunologic diseases or for improvement of cognition, said method comprising administering to a patient in need of such a treatment a therapeutically effective amount of an active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands.

### Claim 28 (depends on 2)

The combination according to claim 2, wherein the binding of said compound of the first component to the 5-HT6-receptor is determined by a Ki value of less than 200 nM.

### Claim 29 (depends on 28)

The combination according to claim 28, wherein the binding of said compound of the first component to the 5-HT6-receptor is determined by a Ki value of less than 100 nM.

### Claim 30 (depends on 7)

The combination according to claim 7, wherein the binding of said NMDA-receptor ligand of the second component to an NMDA-receptor is determined by an EC50 or IC50 value of less than 100 μM.

### Claim 31 (depends on 7)

The combination according to claim 7, wherein the second component comprises memantine.

### Claim 32 (depends on 8)

The combination according to claim 8, comprising 10-80% by weight of the first component and 80-20% by weight of the second component, referring to the total weight of both components.

### Claim 33

A method for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, irritable bowel syndrome, Alzheimer's, Parkinson's or Huntington's Disease, said method comprising administering to a patient in need of such a treatment a therapeutically effective amount of an active substance combination comprising one or more compounds with 5-HT6 receptor affinity and one or more NMDA-receptor ligands.
